NEW YORK (GenomeWeb) – Rosetta Genomics said today that it intends to sell its PersonalizeDx business as part of an ongoing effort to focus on its microRNA-based thyroid nodule classification assay, RosettaGx Reveal.
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.